INTRODUCTION {#SEC1}
============

EVI1 is a transcriptional regulator with an essential role in early development and hematopoiesis ([@B1]). However, aberrantly high expression of *EVI1*, which frequently results from chromosomal aberrations involving MECOM (MDS-EVI1 complex) locus on 3q26, where *EVI1* is encoded, has potent oncogenic properties with transformation capabilities *in vivo* and *in vitro* ([@B4],[@B5]). In acute myeloid leukemia (AML) high *EVI1* expression is associated with poor response to cytotoxic treatment and adverse outcome ([@B6],[@B7]). *EVI1* overexpression has been linked to leukemic transformation in children undergoing gene therapy ([@B8]), and individuals affected by Fanconi Anaemia (FA), which is an inherited DNA damage response defect with cancer predisposition ([@B9],[@B10]). High *EVI1* expression conferring resistance to cytotoxic treatment and poor prognosis is also seen in other malignancies ([@B11]). Modulation of transcription by EVI1 is not understood in detail, and might, as for other transcriptional regulators, be partly dependent on the cell context of the *EVI1* overexpression event ([@B15],[@B16]). Thus, *EVI1*-coregulated genes are variable in different types of leukemia ([@B17]), but nonetheless transcriptional patterns mediated by EVI1 in AML are enriched for genes involved in metabolic processes, differentiation and proliferation, and affect metabolic dependence on mitochondrial creatine kinase ([@B18],[@B19]). Several transcripts are encoded in the MECOM locus, of which the main transcript encodes the 145 kDa EVI1 nuclear protein, which consists of an N-terminal zinc finger domain with seven motifs, a proline rich central repressor domain, a smaller C-terminal zinc finger domain with three motifs, and a carboxyterminal acidic domain. EVI1 modulates transcription by direct interaction of its zinc fingers with specific DNA sequences ([@B20],[@B21]), and also via recruitment of other transcriptional regulators and chromatin modelling factors ([@B22]), which promotes the concept of EVI1 as a mediator of epigenetic changes that maintain a stem cell like phenotype with transforming capability ([@B3]). Specifically, the interaction of EVI1 with the co-repressor C-terminal binding protein 1 (CtBP1) has been shown to be essential for EVI1-mediated transformation ([@B26],[@B27]). As post-translational modifications of EVI1 have been implicated in modulation of transforming ability and EVI1 protein interactions ([@B28],[@B29]), we further investigated the role of phosphorylation in modulating EVI1 function. We report here on carboxy-terminal phosphorylation in response to genotoxic stress and associated consequences for EVI1 function. These define an opportunity for ameliorating treatment of diseases associated with EVI1 overexpression by targeting ATM kinase.

MATERIALS AND METHODS {#SEC2}
=====================

Cell lines and tissue culture {#SEC2-1}
-----------------------------

The FA-derived AML cell line SB1690CB, which expresses high levels of EVI1, and the EVI1 negative AML cell line OCI-AML5 were maintained as described previously ([@B10]). HEK293T cells and Rat1 fibroblasts were used as previously described ([@B28]). Genotoxic stress was induced by treatment with H~2~O~2~ at concentrations previously used ([@B30]), or irradiation using a 320 kV X-ray system (Gulmay Medical Ltd) for suspension culture leukemia cells or using the image-guided micro-irradiation system for 96 well plates provided via the SARRP research platform (Xstrahl). Induction of activation of the DNA damage response was confirmed by demonstration of increased quantities of γH2AX foci and p53 phosphorylation. ATM inhibition was achieved with pretreatment for 1 h in the presence of 10 μM of the ATM-inhibitor KU55933 (Torcis).

Antibodies {#SEC2-2}
----------

For detection of human EVI1 a polyclonal antibody raised against the N-terminal EVI1 epitope MKSEDYPHETMAPDI (Eurogentec), and the EVI1 antibodies \#2265 and \#2593 (Cell Signaling Technology, CST) were used. For detection of phosphorylated EVI1 we used phospho-specific, affinity purified rabbit polyclonal antibodies raised against EVI1-phospho-peptides NSNHGSQpSPRNVEC for serine 860 (S860) phosphorylation (anti-pS860-EVI1), and NSNHGpSQpSPRNVEC for serine 858 and serine 860 (S858/S860) double phosphorylation (anti-pS858/pS860-EVI1) (Eurogentec) (further details [Supplementary Figure S1](#sup1){ref-type="supplementary-material"}). For other antibodies see [Supplementary Material Table S1](#sup1){ref-type="supplementary-material"}.

Immunoprecipitation, co-immunoprecipitation and western Blot {#SEC2-3}
------------------------------------------------------------

Cell lysis and immunoprecipitation were carried out as previously described ([@B28]). EVI1 was immunoprecipitated with EVI1 antibody \#2593 (Cell Signaling) and captured with protein A sepharose beads. For immunoprecipitation of flag-tagged proteins transfected cells were incubated for one hour with FlagM2 magnetic beads (Sigma). Protein electrophoresis and western blots were carried out using standard methodologies ([@B28]). For quantitation of non-saturated western blot signals see [Supplementary Methods](#sup1){ref-type="supplementary-material"} and [Supplementary Figure S2](#sup1){ref-type="supplementary-material"}.

Mass spectrometry {#SEC2-4}
-----------------

Immunoprecipitated EVI1 from 6 × 10^8^ SB1690CB AML cells was analyzed using multiple reaction monitoring-initiated detection and sequencing (MIDAS) ([@B31]). Following gel electrophoresis, the EVI1 containing band was excised and digested with trypsin. Peptides were separated by liquid chromatography prior to MIDAS using electrospray mass spectrometry on a 4000 Q-TRAP mass spectrometer (AB Sciex). MRM transitions were designed to detect 7--24 amino acid EVI1 peptides with serine, threonine or tyrosine phosphorylation within a Q1 *m/z* range from 400 to 1300 and in both a double and triple charge state. A Q3 mass of either 216.0 Da or Q1 minus 98 Da was used to identify tyrosine or serine/threonine phosphorylation, respectively. MS/MS data were interrogated using MASCOT and confirmed by manual inspection of spectra.

Plasmids and site directed mutagenesis {#SEC2-5}
--------------------------------------

The human EVI1 coding region was excised from pBABE-puro-flag-EVI1 (gift from Aubrey Thompson) ([@B32]) using SalI and EcoRI restriction sites and inserted into the SalI and EcoRI sites of pCMV-flag-5a. Substitution of S858 and S860 for alanine (A) to create the vector pCMV-EVI1-AQA-flag was done by site-directed mutagenesis using the QuikChange^®^ II XL Kit (Agilent). The Codon-optimized mouse Evi1 lentiviral vector pRRL.PPT.SF.EVI1mCo.IRES_EGFP.pre ([@B19],[@B33],[@B34]) was mutated as above to generate pRRL.PPT.SF.EVI1mCoAQA.IRES_EGFP.pre. Control pRRL.PPT.SF.IRES_EGFP.pre was generated by excision of the EVI1-ORF from pRRL.PPT.SF.EVI1mCo.IRES_EGFP.pre vector with BamHI restriction enzyme and re-ligated to create an empty backbone vector. Lentiviral packaging vectors pHCMV-G, pMDLg/pRRE and pRSV-Rev were used as described ([@B35]). Primer sequences are provided in the [Supplementary Table S3](#sup1){ref-type="supplementary-material"}. Confirmation of mutated sequence is illustrated in [Supplementary Figure S3](#sup1){ref-type="supplementary-material"}.

Gene expression analysis {#SEC2-6}
------------------------

Reporter gene assays were carried out in HEK293T cells as described before (details in [Supplementary Material](#sup1){ref-type="supplementary-material"}) ([@B28]), with RT-PCR monitored *EVI1-*expression ([Supplementary Figure S4A](#sup1){ref-type="supplementary-material"}). For Poly-A RNA sequencing (RNA*seq*) analysis of EVI1-mediated modulation of gene expression RNA was extracted from HEK293 cells, which were subjected to transient transfection using half confluent cultures with pCMV-flag, pCMV-EVI1-WT-flag or pCMV-EVI1-AQA-flag, exposed to 150 μM H~2~O~2~ or left untreated for 8 h. Equal levels of EVI1 levels were monitored by western blot ([Supplementary Figure S4B](#sup1){ref-type="supplementary-material"}). Libraries were prepared with the Lexogen QuantSeq 3′ mRNA-Seq Library Prep Kit for Illumina (FWD) using an input of 200 ng and performing 14 cycles of amplification. Indexed libraries were then quantified using the Kapa Illumina Library quantification kit (Cat. 07960336001) and pooled. 1 × 75 bp sequence reads were generated by clustering 2.0 pM of the library pool on a NextSeq500 High throughput run. Ordered BAM files were generated against the human genome feature file Homo_sapiens.GRCh38.90.gtf downloaded from Ensembl (<ftp://ftp.ensembl.org/pub/current_gtf>) ([@B36]). Data analysis was performed using Qlucore Omics Explorer 3.3 (Qlucore, Lund, Sweden) with a FPKM (Fragments Per Kilobase Million) cut-off of 10. To identify significant differentially regulated transcripts, RNAseq expression data analysis was carried out by applying a group ANOVA with *P* \< 0.01 to the entire dataset. For illustration of the comparisons between the effect on transcription with EVI1-WT and EVI1-AQA in relation to untransfected cells and empty vector-transfected control cells with and without DNA damage, values were normalized to the mean of 0 and a variance of one. In addition, differences between expression levels at individual conditions were assessed by two group comparison (*t*-test). Biological pathways associated with differential gene expression were determined using a right-sided Fisher\'s exact test (Ingenuity Pathways Analysis, Qiagen). The effect on levels of expression detected by RNA*seq* were confirmed by RT-PCR for selected transcripts using *taqman* technology with housekeeper transcripts (*YWHAZ* and *β-ACTIN)* chosen from a tested pool of housekeeper genes for minimal variation between samples and conditions (primer sequences and detailed methodology in [supplementary material](#sup1){ref-type="supplementary-material"}). RT-PCR data was processed for ΔΔ--CT calculation normalized to housekeeping transcripts.

Rat-1 fibroblast transformation assay {#SEC2-7}
-------------------------------------

Retroviral transduction of Rat-1 fibroblasts with human EVI1 was carried out as described previously ([@B28]), using FUGENHD (Promega)- transfected packaging Plat-E cells (MSCV-EVI1-IRES-GFP, MSCV-EVI1-AQA-IRES-GFP or empty vector control MSCV-IRES-GFP). After 4 days cells were FACS-sorted by GFP, and equal levels of EVI1 expression were confirmed by western blot ([Supplementary Figure S5A--C](#sup1){ref-type="supplementary-material"}). GFP^+^ cells (10^4^) were seeded in untreated methylcellulose medium (MethoCult™ M3231, Stem Cell Technology), or supplemented with 30 μM of H~2~O~2~. Alternatively, 1 × 10^5^ cells in 100 μl (96-well plate) were left untreated or irradiated (0.5 or 2 Gy). After 14 days, colony number and size were quantified and documented using a DMIL inverted microscope fitted with a MC170 HD camera (Leica) ([Supplementary Figure S5D](#sup1){ref-type="supplementary-material"}). Induction of DNA damage was assessed by induction of γH2AX foci ([Supplementary Figure S5E](#sup1){ref-type="supplementary-material"}).

Serial replating of hematopoietic progenitors {#SEC2-8}
---------------------------------------------

Hematopoietic c-Kit^+^ progenitor cells were isolated from bone marrow of 8--10 week old C57/BL6 mice as previously described ([@B28],[@B37]). Lentiviral mediated transduction was carried out with EVI1 vectors pRRL.PPT.SF.EVI1mCo.IRES_EGFP.pre, and site mutated pRRL.PPT.SF.EVI1mCoAQA.IRES_EGFP.pre as described ([@B19],[@B38]). In brief, cells cultured in medium supplemented with 4 μg/ml protamine (Sigma) were sequentially infected with two viral batches by spinoculation (60 min at 1250 × *g* at 32°C), and cultured for two days in pre-stimulation serum free cytokine supplemented medium (StemCell Technologies), prior to FACS selection of GFP^+^ cells. Equal transduction efficiency for EVI1-WT and EVI1-AQA was monitored by RT-PCR and quantitation of fluorescent signal ([Supplementary Figures S6A and B](#sup1){ref-type="supplementary-material"}). For replating 2 × 10^4^ GFP^+^ cells were plated in cytokine supplemented Methocult M3231 medium, without and with H~2~O~2~ at the prior demined IC~50~ dose (30 μM), with induction of genotoxic stress monitored by the induction of γH2AX foci ([Supplementary Figure S6C and D](#sup1){ref-type="supplementary-material"}). After 7 days in culture, colonies were counted and morphologically assessed ([Supplementary Figure S6E](#sup1){ref-type="supplementary-material"}). Then cells were harvested, and 2 × 10^4^ cells were replated as before. Colonies were scored for subsequent rounds of replating as above, and previously H~2~O~2~ treated colonies were split and either treated again or left untreated. For morphological assessment cytospin preparations were stained with May-Grünwald Giemsa ([Supplementary Figure S6F](#sup1){ref-type="supplementary-material"}), and 200 cells per preparation were assessed.

Immunofluorescence (IF) {#SEC2-9}
-----------------------

For immunofluorescence cells were incubated with antibodies following standard procedures and image generation. Spatial association of EVI1 and CtBP1 was quantified by determining linear signal correlation by Pearson product-moment correlation coefficient ([@B39]) (further details in [Supplementary Methods](#sup1){ref-type="supplementary-material"}). Induction of the DNA damage response was confirmed by demonstration of increased frequency of γH2AX foci ([Supplementary Figure S7](#sup1){ref-type="supplementary-material"})

RESULTS {#SEC3}
=======

DNA damage mediates sequential phosphorylation of EVI1 on the carboxy-terminal SQS motif {#SEC3-1}
----------------------------------------------------------------------------------------

To identify phosphorylation events on EVI1, we carried out a selective reaction monitoring mass spectrometric analysis of endogenously expressed EVI1 immunoprecipitated from EVI1-overexpressing SB1690CB AML cells. Under standard conditions we identified the HFIGNSNHGSQSPR (aa 849--862) peptide (NCBI accession: NP_001098548.2) (Figure [1A](#F1){ref-type="fig"}). This peptide was also identified with a single site of phosphorylation (HFIGNSNHGSQpSPR), for which the MS/MS spectrum indicated serine phosphorylation at S860 (Figure [1B](#F1){ref-type="fig"}). This peptide involves an ATM (ataxia telangiectasia mutant)---kinase specific SQS motif ([@B40]), which is conserved across species (Figure [1C](#F1){ref-type="fig"}). We exposed cells to genotoxic stress by irradiation or H~2~O~2~, and confirmed induction of DNA damage by demonstration of increased γH2AX foci and p53 phosphorylation (Figure [1D](#F1){ref-type="fig"}). Mass spectrometric analysis of immunoprecipitated EVI1 after DNA damage uncovered a doubly phosphorylated EVI1-peptide at residues S858 and S860 (Figure [1E](#F1){ref-type="fig"}). Western blot analysis of EVI1 using antibodies specifically raised against EVI1 peptides phosphorylated only at S860, or S858 plus S860 respectively, confirmed a rapid induction of doubly phosphorylated EVI1 both at S858 and S860 together after irradiation or H~2~O~2~ treatment. This event was only detectable at very low levels in non-stressed cells, while correspondingly the signal for single phosphorylation at S860 decreased (Figure [2A](#F2){ref-type="fig"}). Pre-treatment with the ATM inhibitor KU55933 reduced the induction of the doubly phosphorylated (S858/S860) EVI1 after IR (Figure [2B](#F2){ref-type="fig"}). Mass spectrometric analysis of EVI1 repeatedly detected non-phosphorylated and EVI1 phosphorylated at S860 in untreated cells. After genotoxic stress EVI1 peptides with double phosphorylation at S858 and S860 were more abundant. However, a peptide indicating single phosphorylation on S858 alone was never detected. These findings suggest that the S858 phosphorylation is dynamically regulated in response to genotoxic stress after S860 phosphorylation.

![*Carboxy-terminal EVI1 phosphorylation*. Mass spectrometry analysis of the EVI1 peptide Asn849-Arg862 from SB1690CB AML cells, demonstrating the presence of non-phosphorylated (**A**) and single Ser860 phosphorylated peptides (**B**) in untreated SB1690CB cells. y- and b-type ions illustrating their position within the peptide sequence indicated. The mass/charge ratio (m/z) of the precursor ion is also shown. (**C**) Schematic representation of the EVI1 protein with sequence alignment of EVI1 from other species as indicated, showing DNA binding zinc finger domains (ZF), CtBP1 binding motifs (CtBP) and acidic domain (AC). Carboxy-terminal phosphorylation sites are shown in red circles and annotated in relation to the EVI1-SQS containing epitope alignment. (**D**) Confirmation of induction of DNA damage by γH2AX foci formation after H~2~O~2~ or radiation treatment of SB1690CB cells (left panel). White arrowheads denote cells with increased number of foci (green signal). DAPI co-stain for the nucleus (blue signal). Western blot (right panel) of *γ*H2AX and p-p53 (Ser15) as markers of DNA damage response activation and ATM activity after H~2~O~2~-treatment of SB1690CB cells. (**E**) EVI1 MS spectrum obtained for peptide Asn849-Arg862 from irradiated SB1690CB cells, inferring double phosphorylation of the carboxy-terminal S858/S860 SQS motif.](gky536fig1){#F1}

![*Induction of EVI1 double phosphorylation by DNA damage*. (**A**) Immunoprecipitated EVI1 from SB1690CB cells probed with anti-pS860-EVI1 (upper panel), and anti-pS858/pS860-EVI1 antibody, untreated (lane 1), and after 1 and 2 h (lane 2 and 3) post radiation. (**B**) Western blot (WB) of EVI1-immunoprecipitates from untreated (lanes 1 and 2) and irradiated (lanes 3 and 4) SB1690CB cells pre-treated (1 h) with 10 μM ATM-kinase inhibitor KU55933 (lanes 2 and 4), and not pre-treated (lanes 1 and 3). Membranes were probed for doubly phosphorylated EVI1 with anti-pS858/pS860-EVI1 antibody. Middle panel: membrane as upper panel re-probed with pan-EVI1 antibody. Lower panel: WB of p-p53 (Ser15) carried out on input samples as positive control for ATM-activity and ATM-inhibition.](gky536fig2){#F2}

EVI1 transcriptional changes in the DNA damage response are sustained by carboxy-terminal SQS-phosphorylation {#SEC3-2}
-------------------------------------------------------------------------------------------------------------

To functionally assess the carboxy-terminal SQS phosphorylation we generated site mutated EVI1constructs to mimic non-phosphorylated, non-phosphorylatable EVI1 (EVI1-AQA), for comparison with the wild type EVI1-SQS (EVI1- WT) constructs. We first assessed target-gene promoter repression of EVI1-AQA compared with EVI1-WT and measured EVI1-mediated repression of *FOS* and *PLZF* ([@B41],[@B42]). EVI1-WT and EVI1-AQA mutant repressed *PLZF* promoter, regulated by the EVI1 N-terminal zinc-finger motif, and C-terminal zinc-finger motif regulated *FOS* promoter equally, indicating that EVI1 promoter repression was not affected by mutation of S858 and S860 (Figure [3A](#F3){ref-type="fig"}). We next compared the effect on transcriptional patterns mediated by EVI1-WT and EVI1-AQA. An RNAs*eq* expression dataset was generated from untransfected, empty vector (vector-), EVI1-WT and EVI1-AQA transfected HEK293 cells, with and without DNA damage mediated by H~2~O~2~. We applied a group ANOVA with *P* \< 0.01 to the entire dataset and identified 1306 significantly differentially expressed transcripts ([Supplementary Table S4](#sup1){ref-type="supplementary-material"}, Sheet 1). Further detailed analysis of untreated EVI1-WT and EVI1-AQA compared to vector only transfected cells by two group comparison showed a strong overlap ([Supplementary Table S4](#sup1){ref-type="supplementary-material"}, Sheet 2): Of 62 significantly (*P* \< 0.05) upregulated transcripts with EVI1-WT transfection compared to empty vector, 22 are also significantly up-regulated in EVI1-AQA transfected cells. Likewise, of 90 significantly repressed transcripts with EVI1-WT transfection, 30 are also significantly repressed in EVI1-AQA transfected cells. However, in the presence of damage, 10 of 41 upregulated transcripts in EVI1-WT transfected cells were also significantly upregulated in EVI1-AQA transfected cells, and of 47 repressed transcripts in EVI1-WT transfected cells, only 7 were also significantly repressed by EVI1-AQA transfection. Pathways affected by EVI1-WT transfection in the presence of genotoxic stress in this model included fucose-carbohydrate biosynthesis, death-receptor- and MAPK signaling ([Supplementary Table S4](#sup1){ref-type="supplementary-material"}, excel file, sheet 3). A heat map of 1306 the differentially expressed transcripts identified by group ANOVA when EVI1-WT and EVI1-AQA were compared with untransfected cells and empty vector control in untreated cells and with H~2~O~2~ mediated DNA damage is clearly divided by vertical clustering in two halves by H~2~O~2~-induced genotoxic stress (Figure [3B](#F3){ref-type="fig"}). In untreated EVI1-transfected cells, horizontal dendrogram delineation separates two main clusters of EVI1-regulated transcripts, compared with non-transfected and vector-control transfected cells (boxed). In cluster 1, containing 139 transcripts, EVI1 mediated lower expression under normal conditions. For cluster 2, containing 328 transcripts, EVI1 mediated higher expression. Strikingly, when comparing heat-map patterns of untreated cells transfected with EVI1-WT with patterns from EVI1-AQA mutant transfected cells, the patterns boxed in cluster 1A and 2A are almost identical. Analysis in the same fashion of cells exposed to genotoxic stress by H~2~O~2~ showed that EVI1-WT mediated expression changes are clustering and largely overlapping with those delineated in untreated cells. However, in the presence of genotoxic stress the expression patterns mediated by EVI1-WT compared to those mediated by EVI1-AQA are more diverse. In the cluster 1B a distinct sub-cluster of 14 transcripts is delineated with decreased expression in untreated EVI1-WT and EVI1-AQA transfected cells, but in response to damage are not repressed in the non-phosphorylatable EVI1-AQA (Figure [3B](#F3){ref-type="fig"}, arrow). In cluster 2B there are multiple transcripts that are higher expressed in untreated and damaged EVI1-WT transfected cells, but not in damaged EVI1-AQA transfected cells, which form a distinct sub-cluster of 93 transcripts (Figure [3B](#F3){ref-type="fig"}, dashed box). The modulatory effect on transcriptional patterns mediated by carboxy-terminal mutated EVI1-AQA is stronger in the presence of genotoxic stress.

![*Effect of EVI1-WT and EVI1-AQA on transcription*. (**A**) Luciferase assays on promoters of EVI1-repressed *PLZF* (left panel) and *FOS* (right panel) transcripts (*n* = 4, *t*-test, ns: not significant). (**B**) Heat map illustration of significantly differentially expressed transcripts (*P* \< 0.01) after transfection with EVI1-WT and EVI1-AQA of untreated cells (left half of the heatmap), and after treatment with H~2~O~2~ (150 μM, right half of the heat map, indicated by black line) (*n* = 1306). The heatmap was generated applying a group ANOVA analysis to the entire dataset. Clusters of EVI1 regulated transcripts were identified by dendrogram delineation, and boxed for repressed (1A and 1B), and upregulated transcripts (2A and 2B). Patterns of sub-clusters in H~2~O~2~ treated cells with different changes comparing EVI-WT with EVI1-AQA indicated by arrow in 1B and dashed box in 2B.](gky536fig3){#F3}

EVI1 carboxy-terminal phosphorylation sustains EVI1 transforming ability in the DNA damage response {#SEC3-3}
---------------------------------------------------------------------------------------------------

To investigate to what extent the double phosphorylation at S858 and S860 also sustains EVI1-mediated transformation, we compared the effect of EVI1-WT with the EVI1-AQA mutant on Rat-1 fibroblast transformation ([@B5]). Equal expression of EVI1-WT and EVI1-AQA constructs in Rat-1 fibroblast cultures and activation of the DNA damage response in transduced cells was confirmed ([Supplementary Figure 5A--E](#sup1){ref-type="supplementary-material"}). Transduction with EVI1-WT resulted in a significant 2.2-fold (mean, *n* = 4) increase in colony numbers after 14 days compared with vector only transduction, which under standard conditions was not significantly different from transduction with mutated EVI1-AQA (Figure [4A](#F4){ref-type="fig"}). However, in the presence of genotoxic stress mediated by H~2~O~2~, EVI1-WT confers a 10.1-fold increase in colony numbers compared to vector only, while EVI1-AQA had a markedly weaker effect (Figure [4B](#F4){ref-type="fig"}). Radiation had a more profound effect on Rat-1 transformation. At 0.5 Gy EVI1-WT conferred doubling of colony numbers, while EVI1-AQA transduction did not significantly increase colony numbers compared with vector only. At 2 Gy only EVI1-WT conferred any significant increase in colony numbers compared to untransduced cells, while no significant increase in colony numbers was seen with EVI1-AQA transfection (Figure [4C](#F4){ref-type="fig"}).

![*EVI1-mediated Rat-1 fibroblast transformation*. (**A**) Rat-1 fibroblast colonies of untransduced, stably MSCV-, EVI1-WT- or EVI1-AQA-transduced fibroblasts. Rat-1 fibroblasts were left untreated, H~2~O~2~-treated (**B**) or irradiated with 0.5 and 2Gy as indicated (**C**) (*n* = 4). Statistical analysis: *t*-test (\**P* \< 0.05, ns: not significant).](gky536fig4){#F4}

The EVI1 carboxy-terminal SQS motif sustains hematopoietic self-renewal {#SEC3-4}
-----------------------------------------------------------------------

Transduction with EVI1 has been shown to increase replating capacity of hematopoietic progenitor cells, reflecting the importance of EVI1 for hematopoietic self-renewal ([@B3],[@B19]). As ATM-knockout leads to haematopoietic stem cell exhaustion ([@B43]), we surmised that the ATM-mediated phosphorylation event at S858/S860 would be linked to EVI1-mediated self-renewal. We confirmed the replating potency of EVI-WT with murine c-Kit^+^ hematopoietic progenitor cells for three rounds of replating, untreated and in the presence of genotoxic stress (Figure [5A](#F5){ref-type="fig"}) (*n* = 8, from eight mice). Transduction with EVI1-AQA did not affect replating efficiency compared to EVI1-WT in the first round of plating (Figure [5B](#F5){ref-type="fig"}); vector only transfected cells also formed colonies. However, when replated in the second and third round, when vector only transduced cells did not form colonies, colony forming capacity of EVI1-AQA was significantly reduced compared with EVI1-WT (Figure [5C](#F5){ref-type="fig"} and [D](#F5){ref-type="fig"}), even more profoundly in the presence of genotoxic stress. In line with these observations and published data ([@B19]), morphological analysis of EVI1-WT transduced colonies revealed a significant proportion of immature myeloid cells with blast-like morphology. Comparing EVI-WT- with EVI1-AQA-transfected colonies uncovered a significantly reduced number of cells with blast-like morphology in EVI1-AQA transduced colonies even in the first round of replating (Figure [5E](#F5){ref-type="fig"} and [F](#F5){ref-type="fig"}). These observations imply that maintenance of a hematopoietic blast-like and self-renewal phenotype by EVI1 is partly dependent on the phosphorylatable carboxy-terminal SQS motif.

![*EVI1-mediated serial replating of murine hematopoietic progenitor cells*. (**A**) Schematic representation of hematopoietic progenitor clonogenic replating: cKit+ cells were transduced, selected for transduction, and plated in the presence or absence of H~2~O~2~ (first round). Colonies were counted after 7 days, harvested and replated (second round). H~2~O~2~ treated cells were split in two batches (red arrows) to be left untreated or treated with a second dose of H~2~O~2~. Untreated cells were re-plated untreated (green arrow). Remaining cells were used for a third round of replating. (**B**) Colony count after first round (*n* = 8, from eight different mice, black: H~2~O~2~ treated). (**C** and **D**) Colony counts after the second and third rounds of replating (*n* = 8, from eight different mice). White: untreated; gray: untreated cells replated from previously H~2~O~2~ treated colonies; black: H~2~O~2~ treatment in all rounds. Inserts C and D: direct comparison between untreated EVI1-WT and EVI1-AQA transduction with and without damage. Statistical analysis: paired *t-*test (\**P* \< 0.05, \*\**P* \< 0.01). (**E**) May-Grünwald Giemsa stained cells from colonies after first culture. Red arrowheads point typical blast-like cell morphology. (**F**) Blast-like cells quantitation from the first round of replating. Statistical analysis: one-way ANOVA (\*\**P* \< 0.01, \*\*\**P* \< 0.001).](gky536fig5){#F5}

Increased spatial association of EVI1 with CtBP1 in response to genotoxic stress {#SEC3-5}
--------------------------------------------------------------------------------

To explain the distinct effect of DNA damage induced phosphorylation on EVI1 transcription and transforming ability we hypothesized that these effects would be mediated by alteration of important EVI1 interactions with other transcriptionally active proteins. This seemed in particular plausible as the carboxy-terminal region has not been implicated in direct interaction of EVI1 with DNA, and SQS to AQA motif mutation had no effect on promoter repression (see above). As the interaction with the co-repressor CtBP1 is essential for EVI1-mediated transformation ([@B22],[@B27]), and CtBP1 itself has a role in the maintenance of genomic integrity and DNA damage response ([@B44],[@B45]), we investigated the effect of EVI1 carboxy-terminal phosphorylation, which does not directly involve the CtBP1 binding sites of EVI1 ([@B27]), on the EVI1-interaction with CtBP1 in the presence of genotoxic stress monitored by induction of γH2AX foci ([Supplementary Figure S7B and C](#sup1){ref-type="supplementary-material"}). As the DNA damage response has been implicated in ATM-mediated phosphorylation determining cellular localization of proteins ([@B40],[@B46],[@B47]), we assessed the nuclear localization of EVI1 in relationship to CtBP1 with and without genotoxic stress. Under non-stressed conditions non-phosphorylatable mutant EVI1-AQA, which cannot be phosphorylated on this ATM consensus site, co-localized with CtBP1 in transfected HEK293T cells to the same degree as EVI1-WT. However, in the presence of genotoxic stress mediated by H~2~O~2~ or radiation, we observed a highly significant increase in spatial association of EVI1-WT with CtBP1 of 22.1% ±- 4.4 SEM with H~2~O~2~ (*n* = 4, *P* \< 0.01), and of 22.7% ± 2.4 SEM after radiation (*P* \< 0.001) (Figure [6A](#F6){ref-type="fig"}, upper two panels and 6B). Non-phosphorylatable EVI1-AQA mutant failed to increase proximity in association with CtBP1 after treatment with H~2~O~2~ or radiation. In endogenously EVI1-expressing SB1690CB AML cells, the highly significant increase in the degree of co-localization with CtBP1 in the presence of genotoxic stress was confirmed with cells with increases of 18.7% ± 3.9 SEM) after H~2~O~2~ treatment, and 24.9% ± 4.8 SEM after radiation (*n* = 3, *P* \< 0.01) (Figure [6A](#F6){ref-type="fig"}, lower panel, and C).

![*Nuclear association of EVI1 with CtBP1*. (**A**) EVI1 (green) and CtBP1 (red) immunofluorescence signal of HEK293T cells transfected with EVI1-WT (upper panel) and EVI1-AQA mutant (middle panel), or SB1690CB AML cells (lower panel) after genotoxic stress induced either with H~2~O~2~ treatment or irradiation (2 Gy). Left top corner inserts represent 4 μm^2^ regions of interests (ROI) in HEK293T cells or 3 μm^2^ ROIs in SB1690CB cells (eight ROIs/cell analyzed). (**B**) Quantification of EVI1 and CtBP1 co-localization in EVI1-WT or EVI1-AQA transfected HEK293T cells after genotoxic stress. Degree of co-localization is expressed as Pearson\'s Coefficient (P'sC). Each bar represents the average P'sC of independent experiments (*n* = 3) for H~2~O~2~ (left panel) and irradiated cells (right panel). (**C**) Distribution of P'sC for endogenously expressed EVI1 and CtBP1 co-localization in SB1690CB leukemia cells after H~2~O~2~ treatment or irradiation. Each dot represents a single cell (left panel). Average P'sC of independent experiments (*n* = 3) plotted as bar graphs (right panel). Statistical analysis: one-way ANOVA (\**P* \< 0.05, \*\**P* \< 0.01, \*\*\**P* \< 0.001, ns = not significant).](gky536fig6){#F6}

Increased EVI1-CtBP1 interaction after genotoxic stress {#SEC3-6}
-------------------------------------------------------

In order to explore if the phosphorylation-mediated increase in co-localization of EVI1 with CtBP1 reflects EVI1 interaction, we performed co-immunoprecipitations using Flag-tagged EVI1-WT and EVI1-AQA in HEK293T cells. Comparing EVI1-WT with EVI1-AQA mutant, the levels of co-immunoprecipitated CtBP1 for EVI1-WT and EVI1-AQA mutant were not different under standard conditions (Figure [7A](#F7){ref-type="fig"} and [B](#F7){ref-type="fig"}). However, the non-phosphorylatable EVI1-AQA mutant showed 36.9% ± 6.1 SEM less co-immunoprecipitated CtBP1 (*P* \< 0.05) after treatment with H~2~O~2~ compared with EVI1-WT (Figure [7C](#F7){ref-type="fig"} and [D](#F7){ref-type="fig"}), implying greater EVI1-CtBP1 affinity after damage-mediated carboxyterminal EVI1-phosphorylation. Thus, the CtBP1-EVI1 interaction in the DNA damage response is promoted by the carboxy-terminal EVI1 phosphorylation, and points to the DNA damage response affecting transcriptionally relevant EVI1 protein complex formations.

![*Effect of genotoxic stress on EVI1-CtBP1 interaction*. (**A**) Western blot analysis of flag-antibody immunoprecipitated tagged EVI1 and co-immunoprecipitated CtBP1 from total cell protein extracts of untreated Flag-tagged EVI1-WT or EVI1-AQA transfected HEK293 cells (upper panel: EVI1; lower panel: CtBP1). (**B**) Signal quantification of serial biological replicates (*n* = 3) at 3 min (n.s. = not significant, *t*-test). (**C**) Western blot analysis of flag-antibody immunoprecipitated EVI1 and co-immunoprecipitated CtBP1 from total cell protein extracts of H~2~O~2~ treated Flag-tagged EVI1-WT and EVI1-AQA transfected cells (upper panel: EVI1; lower panel CtBP1). (**D**) Signal quantification of biological replicates (*n* = 3) (\**P* \< 0.05, *t*-test).](gky536fig7){#F7}

DISCUSSION {#SEC4}
==========

EVI1 is essential for early development, and further insight into EVI1 function will help to define its role in maintenance of the stem cell phenotype. In view of the clinical relevance of aberrantly high expression of EVI1 for malignant proliferation, better understanding of EVI1 functions will potentially also open novel therapeutic perspectives for EVI1 overexpressing malignancies. Our mass spectrometry- and antibody-based analysis of *endogenously* expressed EVI1 in SB1690CB AML cells confirms phosphorylation of the carboxy-terminal SQS site (S858 and S860). Carboxy-terminal phosphorylation of EVI1 has previously been listed in global phosphoproteomic and targeted studies ([@B29],[@B40],[@B48]), but has not been further characterized or functionally assessed in any detail. We detected EVI1 not phosphorylated at this motif, phosphorylated at S860, or doubly phosphorylated at S860 and S858 after induction of DNA damage. Building on previously published studies as above ([@B29],[@B40],[@B48]), our data imply that the S860 phosphorylation is likely to be present during normal cell proliferation, while the double phosphorylation on S860 and S858 is promoted via ATM, in particular in response to genotoxic stress. Reduction of the level of double phosphorylation with an ATM-inhibitor is in line with the recognition of the SQS-sequence as a specific ATM motif ([@B40]). Given the role of ATM in stem cell self-renewal ([@B43]), and EVI1 for maintenance of the stem cell phenotype ([@B1]), we hypothesized a role of the carboxy-terminal SQS motif for this EVI1 function, which we investigated by EVI1 site directed mutagenesis and gene transfer. We first show that the modulatory effect mediated by EVI1 on transcriptional patterns the presence genotoxic stress is dependent on the carboxy-terminal SQS motif. Aware of the limitations using the HEK293 model for investigating EVI1-target genes, we noted that known EVI1-affected transcripts such as *ALDOC* ([@B18]) were amongst significantly differentially expressed transcripts also in our model, and further investigations in respect of EVI1-modulated gene expression in particular in the presence of genotoxic stress, which in our model affected distinct cellular pathways, will be important to understand EVI1-mediated transcriptional modulation. In addition, in a clinical context modulation of EVI1-mediated gene expression by genotoxic stress and ATM, for example in response to chemotherapy, is likely to be relevant for gene expression patterns in EVI1-expressing leukaemia and solid tumors also in patient samples. We demonstrated the relevance of the carboxy-terminal SQS phosphorylation with respect to EVI1-mediated transformation using Rat-1 fibroblasts, for which in the presence of genotoxic stress only phosphorylatable EVI1-WT sustains transformation, while EVI1-AQA lacking the ATM consensus site had reduced transforming ability. In murine haematopoietic progenitor cell replating, modelling the EVI1-function in early hematopoiesis, mutation of the carboxy-terminal ATM motif SQS to AQA significantly reduced re-plating capacity. ATM is required for the regulation of oxidative stress for self-renewal of hematopoietic cells ([@B43]), and *EVI1* expression is high in early haematopoietic cells ([@B49]). Thus, EVI1 mediated hematopoietic self-renewal or maintenance capacity is likely linked by an ATM-EVI1 axis, which is supported by the demonstration of reduced self-renewal mediated by EVI1-AQA, which lacks the ATM consensus site. But how is this achieved when mutation of the carboxy terminal SQS motif does affect DNA-binding and zinc finger motifs of EVI1, and does not alter gene promotor repression? We show that the EVI1-interaction with CtBP1 is dynamically and finely modulated by the ATM-mediated EVI1-SQS phosphorylation and enhanced by genotoxic stress. The interaction with CtBP1 is essential for EVI1 function with respect to transformation and leukaemogenesis in murine haematopoietic progenitor cells ([@B27],[@B50]), and modulated by ATM without directly affecting previously described CtBP1 binding regions, which involve amino acids 553--559 and 584--590 ([@B27]). This might involve charge-mediated affinity between proteins, altered tertiary structure, or posttranslational modification of CtBP1 or other proteins, which we are investigating. Data presented here support a concept by which EVI1 phosphorylation links ATM and the DNA damage response to essential EVI1 protein interactions for transcriptional regulation, transformation and self-renewal. This novel aspect of EVI1 function, in particular with respect to transformation and self-renewal, is therapeutically relevant for EVI1-overexpressing malignancies, as chemotherapy induced genotoxicity might detrimentally sustain EVI1 function. Inhibition of ATM with an orally applicable compound ([@B51]) is currently subject to phase 1 clinical evaluation and has shown activity in a murine leukaemia model ([@B52]). ATM inhibition or therapeutic interference of the enhanced EVI1 interaction with CtBP1 after genotoxic stress might be of particular benefit in EVI1 overexpressing malignancies, and this will be subject to further work.
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